Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells

Liu,Yingtao; Tao,Xiang; Jia,Luoqi; Cheng,Kwai  Wa; Lu,Yiling; Yu,Yinhua; Feng,Youji

doi:10.3892/mmr.2012.1052

Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells

Authors:
- Yingtao Liu
- Xiang Tao
- Luoqi Jia
- Kwai Wa Cheng
- Yiling Lu
- Yinhua Yu
- Youji Feng
View Affiliations

Affiliations: Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, P.R. China, Department of Systems Biology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77054, USA
Published online on: August 28, 2012 https://doi.org/10.3892/mmr.2012.1052
Pages: 1006-1012

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RAB25 belongs to the Rab family of small GTPases and is implicated in the development of various types of human cancer. To evaluate the role of RAB25 in ovarian cancer, RAB25 was knocked down by siRNA in HEY and ES‑2 human ovarian cancer cells. Autophagy, cell growth and cell apoptosis were evaluated. The results showed that knockdown of RAB25 increased acidic vesicle organelles and GFP-microtubule-associated protein 1 light chain 3 punctate fluorescence in ovarian cancer cells. Autophagy that promoted by knockdown of RAB25 was not observed in cells where the ERK1/2 signaling pathway had been inhibited by U0126. Knockdown of RAB25 reduced cell cycle progression and cell growth. Apoptosis of ovarian cancer cells could be induced by knockdown of RAB25. These results support the tumorigenic role of RAB25 in ovarian cancer cells.

View Figures

View References

1	Colombo N, Van Gorp T, Parma G, et al: Ovarian cancer. Crit Rev Oncol Hematol. 60:159–179. 2006. View Article : Google Scholar
2	Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med. 354:34–43. 2006.
3	Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 20:1248–1259. 2002.
4	Shih IeM and Davidson B: Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 5:1641–1657. 2009.PubMed/NCBI
5	Pisano C, Bruni GS, Facchini G, et al: Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 5:421–426. 2009.PubMed/NCBI
6	Nelson AE, Francis JE and Zorbas H: Population screening and early detection of ovarian cancer in asymptomatic women. Aust N Z J Obstet Gynecol. 49:448–450. 2009. View Article : Google Scholar : PubMed/NCBI
7	Marth C, Hiebl S, Oberaigner W, et al: Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology. Int J Gynecol Cancer. 19:94–102. 2009.
8	Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000.
9	Goldenring JR, Shen KR, Vaughan HD, et al: Identification of a small GTP-binding protein, RAB25, expressed in the gastrointestinal mucosa, kidney, and lung. J Biol Chem. 268:18419–18422. 1993.
10	He H, Dai F, Yu L, et al: Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 10:231–242. 2002.
11	Mor O, Nativ O, Stein A, et al: Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene. 22:7702–7710. 2003.PubMed/NCBI
12	Cheng KW, Lahad JP, Kuo WL, et al: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 10:1251–1256. 2004.
13	Caswell PT, Spence HJ, Parsons M, et al: Rab25 associates with alpha 5 beta 1 integrin to promote invasive migration in 3D microenvironments. Dev Cell. 13:496–510. 2007.
14	Cheng KW, Lu YL and Mills GB: Assay of Rab25 function in ovarian and breast cancers. Method Enzymol. 403:202–215. 2005.
15	Fan Y, Xin XY, Chen BL, et al: Knockdown of Rab25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 38:561–567. 2006.
16	Tsujimoto Y and Shimizu S: Another way to die: autophagic programmed cell death. Cell Death Differ. 12:1528–1534. 2005.
17	Lum JJ, Bauer DE, Kong M, et al: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 120:237–248. 2005.
18	Ogier-Denis E and Codogno P: Autophagy: a barrier or an adaptive response to cancer. Biochim Biophys Acta. 1603:113–128. 2003.
19	Qu XP, Yu J, Bhagat G, et al: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 112:1809–1820. 2003.
20	Mathew R, Karp CM, Beaudoin B, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137:1062–1075. 2009.
21	Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, et al: Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 67:2217–2225. 2007.
22	Ulasov IV, Sonabend AM, Nandi S, et al: Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer. 100:1154–1164. 2009.
23	Paglin S, Hollister T, Delohery T, et al: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 61:439–444. 2001.
24	Wu WK, Cho CH, Lee CW, et al: Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy. 6:228–238. 2010.PubMed/NCBI
25	Mujumdar N, Mackenzie TN, Dudeja V, et al: Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology. 139:598–608. 2010. View Article : Google Scholar
26	Wang J, Whiteman MW, Lian H, et al: A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1. J Biol Chem. 284:21412–21424. 2009.
27	Subramaniam S and Unsicker K: Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience. 138:1055–1065. 2006.
28	Goldenring JR and Nam KT: Rab25 as a tumour suppressor in colon carcinogenesis. Br J Cancer. 104:33–36. 2011.
29	Caswell PT, Spence HJ, Parsons M, et al: Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell. 13:496–510. 2007.
30	Cheng JM, Volk L, Janaki DK, et al: Tumor suppressor function of Rab25 in triple-negative breast cancer. Int J Cancer. 126:2799–2812. 2009.
31	Cheng JM, Ding M, Aribi A, et al: Loss of RAB25 expression in breast cancer. Int J Cancer. 118:2957–2964. 2006.
32	Chatterjee SJ and Pandey S: Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol Ther. 11:216–228. 2011.
33	Schnekenburger M, Grandjenette C, Ghelfi J, et al: Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. Biochem Pharmacol. 81:364–378. 2011.
34	Cagnol S and Chambard JC: ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J. 277:2–21. 2010.
35	Mebratu Y and Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle. 8:1168–1175. 2009.
36	Glading A, Koziol JA, Krueger J, et al: PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res. 67:1536–1544. 2007.
37	Mebratu YA, Dickey BF, Evans C, et al: The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death. J Cell Biol. 183:429–439. 2008.